Ofatumumab

Red

Brand Name(s):Kesimpta

Indication:Relapsing–remitting multiple sclerosis

Rationale:1,2

Considered:Jun-21

Review Date:Jun-26

Comments:
NICE TA699 recommends Ofatumumab as an option for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features. This is only if the company provides ofatumumab according to the commercial arrangement.